[go: up one dir, main page]

JP2013537539A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537539A5
JP2013537539A5 JP2013524239A JP2013524239A JP2013537539A5 JP 2013537539 A5 JP2013537539 A5 JP 2013537539A5 JP 2013524239 A JP2013524239 A JP 2013524239A JP 2013524239 A JP2013524239 A JP 2013524239A JP 2013537539 A5 JP2013537539 A5 JP 2013537539A5
Authority
JP
Japan
Prior art keywords
antibody
medicament according
binds
monoclonal antibody
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013524239A
Other languages
Japanese (ja)
Other versions
JP2013537539A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/047532 external-priority patent/WO2012021773A1/en
Publication of JP2013537539A publication Critical patent/JP2013537539A/en
Publication of JP2013537539A5 publication Critical patent/JP2013537539A5/ja
Pending legal-status Critical Current

Links

Claims (28)

ａ．ＩＬ−１β／ＩＬ−１８二重特異性抗体；又は
ｂ．ＩＬ−１β及びＩＬ−１８に結合する抗体；又は
ｃ．ＩＬ−１βに結合する抗体及びＩＬ−１８に結合する抗体
から選択される一又は複数の抗体を含有する医薬であって、前記パートａ、ｂ、又はｃの一又は複数の抗体は、細胞又は組織においてＩＬ−１β及びＩＬ−１８活性を中和し又は遮断することができる抗体である医薬。 a . An IL-1β / IL-18 bispecific antibody; or b. An antibody that binds to IL-1β and IL-18; or c. Antibodies that bind to IL-1β and antibodies that bind to IL-18
A medicament comprising one or more antibodies selected from the above, wherein the one or more antibodies of part a, b, or c neutralize IL-1β and IL-18 activity in a cell or tissue, or A drug that is an antibody that can be blocked. 抗体がヒト化されている請求項１に記載の医薬。The medicament according to claim 1, wherein the antibody is humanized. パート（ｂ）の抗体が二重作用抗体である請求項１に記載の医薬。The medicament according to claim 1, wherein the antibody of part (b) is a double acting antibody. パート（ｃ）の少なくとも一つの抗体がモノクローナルである請求項１に記載の医薬。The medicament according to claim 1, wherein at least one antibody of part (c) is monoclonal. パート（ｃ）のそれぞれの抗体がモノクローナルである請求項１に記載の医薬。The medicament according to claim 1, wherein each antibody of part (c) is monoclonal. パート（ｃ）の複数の抗体が同時に又は継続的に投与される請求項１に記載の医薬。 The medicament according to claim 1, wherein the plurality of antibodies of part (c) are administered simultaneously or continuously. 抗体が１時間以内で投与される請求項６に記載の医薬。The medicament according to claim 6, wherein the antibody is administered within 1 hour. 免疫疾患又は自己免疫疾患又は炎症性若しくは自己炎症性疾患の治療のための請求項１に記載の医薬。 The medicament according to claim 1 for the treatment of immune or autoimmune diseases or inflammatory Moshiku is autoinflammatory disease. インフラマソーム媒介疾患の治療のための請求項１に記載の医薬。 The medicament according to claim 1 for the treatment of Lee Nfuramasomu mediated diseases. ＩＬ−１β関連疾患の治療のための請求項１に記載の医薬。 The medicament according to claim 1 for the treatment of I L-l [beta] related disease. ＩＬ−１８関連疾患の治療のための請求項１に記載の医薬。 The medicament according to claim 1 for the treatment of I L-18-related diseases. ＩＬ−１β／ＩＬ−１８関連疾患の治療のための請求項１に記載の医薬。 The medicament according to claim 1 for the treatment of I L-1β / IL-18-related diseases. 加齢黄斑変性（ＡＭＤ）の治療のための請求項８に記載の医薬。 The medicament of claim 8 for the treatment of age-related macular degeneration (AMD). ２型糖尿病（Ｔ２Ｄ）の治療のための請求項８に記載の医薬。9. A medicament according to claim 8 for the treatment of type 2 diabetes (T2D). 炎症性腸疾患（ＩＢＤ）の治療のための請求項８に記載の医薬。 The medicament of claim 8 for the treatment of inflammatory bowel disease (IBD). ＩＢＤがクローン病（ＣＤ）である請求項１５に記載の医薬。The medicament according to claim 15, wherein the IBD is Crohn's disease (CD). ＩＢＤが潰瘍性大腸炎（ＵＣ）である請求項１５に記載の医薬。The medicament according to claim 15, wherein the IBD is ulcerative colitis (UC). 患者が抗ＴＮＦ療法に反応しない請求項１に記載の医薬。The medicament according to claim 1, wherein the patient does not respond to the anti-TNF therapy. 有効量のＩＬ−１βに結合するモノクローナル抗体及びＩＬ−１８に結合するモノクローナル抗体を含む医薬。Monoclonal antibody including pharmaceutical to bind to the monoclonal antibody and IL-18 binding to effective amounts of IL-l [beta]. 細胞又は組織においてＩＬ−１β及び／又はＩＬ−１８活性を中和又は遮断する方法であって、ＩＬ−１βに結合するモノクローナル抗体及びＩＬ−１８に結合するモノクローナル抗体に前記細胞又は組織を接触させ、それにより前記活性を中和又は遮断することを含む方法。  A method for neutralizing or blocking IL-1β and / or IL-18 activity in a cell or tissue, wherein the cell or tissue is contacted with a monoclonal antibody that binds to IL-1β and a monoclonal antibody that binds to IL-18. And thereby neutralizing or blocking said activity. ＩＬ−１βに結合する前記モノクローナル抗体及びＩＬ−１８に結合する前記モノクローナル抗体が、同時に又は継続的に投与される請求項１９に記載の医薬。The medicament according to claim 19, wherein the monoclonal antibody that binds to IL-1β and the monoclonal antibody that binds to IL-18 are administered simultaneously or continuously. 前記細胞は、ＩＬ−１βに結合する前記モノクローナル抗体及びＩＬ−１８に結合する前記モノクローナル抗体に同時に又は継続的に接触させられる請求項２０に記載の方法。  21. The method of claim 20, wherein the cells are contacted simultaneously or continuously with the monoclonal antibody that binds IL-1β and the monoclonal antibody that binds IL-18. 細胞又は組織においてＩＬ−１β及び／又はＩＬ−１８活性を中和又は遮断する薬剤でAgents that neutralize or block IL-1β and / or IL-18 activity in cells or tissues あって、ＩＬ−１βに結合するモノクローナル抗体及びＩＬ−１８に結合するモノクローA monoclonal antibody that binds to IL-1β and a monochrome that binds to IL-18 ナル抗体を含有し、ＩＬ−１βに結合するモノクローナル抗体及びＩＬ−１８に結合するContains a null antibody and binds to IL-1β monoclonal antibody and IL-18 モノクローナル抗体に前記細胞又は組織が接触させられ、それにより前記活性が中和又はThe cell or tissue is contacted with a monoclonal antibody so that the activity is neutralized or 遮断される薬剤。Drugs to be blocked. 前記細胞は、ＩＬ−１βに結合する前記モノクローナル抗体及びＩＬ−１８に結合するThe cells bind to the monoclonal antibody that binds to IL-1β and IL-18. 前記モノクローナル抗体に同時に又は継続的に接触させられる請求項２３に記載の薬剤。24. The agent of claim 23, wherein the agent is contacted with the monoclonal antibody simultaneously or continuously. ＩＬ−１β及びＩＬ−１８活性を中和又は遮断する抗体。  Antibodies that neutralize or block IL-1β and IL-18 activity. 抗体が二重特異性抗体である請求項２５に記載の抗体。26. The antibody of claim 25 , wherein the antibody is a bispecific antibody. 抗体がヒト化されている請求項２５に記載の抗体。26. The antibody of claim 25 , wherein the antibody is humanized. 抗体がＩＬ−１β及びＩＬ−１８に結合する請求項２５に記載の抗体。26. The antibody of claim 25 , wherein the antibody binds to IL-1β and IL-18.
JP2013524239A 2010-08-13 2011-08-12 Antibodies against IL-1β and IL-18 for the treatment of disease Pending JP2013537539A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37376010P 2010-08-13 2010-08-13
US61/373,760 2010-08-13
PCT/US2011/047532 WO2012021773A1 (en) 2010-08-13 2011-08-12 Antibodies to il-1beta and il-18, for treatment of disease

Publications (2)

Publication Number Publication Date
JP2013537539A JP2013537539A (en) 2013-10-03
JP2013537539A5 true JP2013537539A5 (en) 2014-10-09

Family

ID=44511598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524239A Pending JP2013537539A (en) 2010-08-13 2011-08-12 Antibodies against IL-1β and IL-18 for the treatment of disease

Country Status (9)

Country Link
EP (1) EP2603525A1 (en)
JP (1) JP2013537539A (en)
KR (1) KR20130100125A (en)
CN (2) CN103154032A (en)
BR (1) BR112013003279A2 (en)
CA (1) CA2808185A1 (en)
MX (1) MX2013001267A (en)
RU (1) RU2013110844A (en)
WO (1) WO2012021773A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707235B1 (en) * 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
HUE044954T2 (en) 2013-03-14 2019-11-28 Univ Laval Electroretinography (erg) system for the assessment of psychiatric disorders
KR20160005044A (en) * 2013-05-17 2016-01-13 제넨테크, 인크. Methods for diagnosing and treating inflammatory bowel disease
CN103554264B (en) * 2013-11-05 2015-08-12 哈尔滨博翱生物医药技术开发有限公司 For bi-specific antibody and the application thereof of IL-1 β and IL-17A
SG11201703458UA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Anti-ang2 antibodies and methods of use
WO2016075034A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
CN107074941A (en) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 Bispecific antibody and for ophthalmologic method
GB201815045D0 (en) * 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN110251657B (en) * 2019-06-14 2020-11-17 中山大学 Application of EBV BRLF1 and functional small peptide thereof in inhibiting activity of inflammatory corpuscles
JP2023519581A (en) 2020-03-26 2023-05-11 ディアメンティス・インコーポレイテッド Systems and methods for processing retinal signal data and identifying conditions
TW202233237A (en) * 2020-11-18 2022-09-01 瑞士商諾華公司 Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
TW202306989A (en) * 2021-06-22 2023-02-16 瑞士商諾華公司 Bispecific antibodies for use in treatment of hidradenitis suppurativa

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577300A (en) 1897-02-16 Printing-press
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4010989A (en) 1975-10-14 1977-03-08 American Hospital Supply Corporation Lockable drawer compartment
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
SE8505922D0 (en) 1985-12-13 1985-12-13 Kabigen Ab CONSTRUCTION OF AN IGG BINDING PROTEIN TO FACILITATE DOWNSTREAM PROCESSING USING PROTEIN ENGINEERING
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
ATE113846T1 (en) 1988-06-21 1994-11-15 Genentech Inc THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL INFARCTS.
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ATE233813T1 (en) 1991-08-14 2003-03-15 Genentech Inc MODIFIED IMMUNOLOBULINS FOR SPECIFIC FC-EPSILON RECEPTORS
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH08500017A (en) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド Bispecific immune adhesin
JPH08500826A (en) 1992-08-21 1996-01-30 ジェネンテク，インコーポレイテッド Methods of treating LFA-1 mediated diseases
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (en) 1992-11-13 1997-01-16 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTIC LIMITED DIFFERENTIATION ANTIQUES FOR THE TREATMENT OF B CELL LYMPHOMA
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
DE69405251T2 (en) 1993-12-10 1998-02-05 Genentech Inc METHODS FOR DIAGNOSIS OF ALLERGY AND TESTING ANTI-ALLERGIC THERAPEUTICS
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
MX9602818A (en) 1994-01-18 1997-06-28 Genentech Inc A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS.
MX9603773A (en) 1994-03-03 1997-07-31 Genentech Inc Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders.
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc Antibody and antibody fragments for inhibiting the growth of tumors
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT877626E (en) 1996-01-23 2003-01-31 Univ Vermont And State Agric C ANTI-CD1 ANTIBODIES FOR USE AGAINST ICTO
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE122004000047I1 (en) 1996-11-27 2005-04-21 Genentech Inc Humanized anti-body against cd11a.
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
ATE516354T1 (en) 1997-05-15 2011-07-15 Genentech Inc APO-2 RECEPTOR
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (en) 1997-12-05 2004-06-15 Scripps Research Inst Method for Production and Humanization of a Mouse Monoclonal Antibody
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000024770A2 (en) 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2001040309A2 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
UA94022C2 (en) * 2000-02-21 2011-04-11 Апплайд Резеч Системз Арс Холдинг Н.В. Use of il-18 inhibitor for the treatment and/or prevention of alcoholic hepatitis
MXPA02010011A (en) 2000-04-11 2003-04-25 Genentech Inc Multivalent antibodies and uses therefor.
JP4955185B2 (en) * 2000-06-29 2012-06-20 アボット・ラボラトリーズ Bispecific antibodies and methods for making and using the same
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (en) 2000-11-30 2013-06-04 Medarex, Inc. Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas
ES2376454T3 (en) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan EXPRESSION BOOKS IN FAGO OF VH HUMAN FRAGMENTS.
EP2845864A3 (en) 2001-05-11 2015-06-10 Amgen, Inc Peptides and related molecules that bind to TALL - 1
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy chain antibody
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DE602004017726D1 (en) 2003-06-30 2008-12-24 Domantis Ltd Pegylated single-domain antibodies (dAb)
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
MXPA06011199A (en) 2004-03-31 2007-04-16 Genentech Inc Humanized anti-tgf-beta antibodies.
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP2520588A1 (en) 2005-08-19 2012-11-07 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090298764A1 (en) * 2006-03-15 2009-12-03 Regents Of The University Of Colorado Gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases
EP2021026A1 (en) * 2006-04-14 2009-02-11 Novartis AG Use of il-i antibodies for treating ophthalmic disorders
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
KR20160017119A (en) * 2007-05-29 2016-02-15 노파르티스 아게 New indications for anti-il-1-beta therapy
WO2009099545A1 (en) * 2008-01-30 2009-08-13 Abbott Laboratories Compositions and methods for crystallizing antibody fragments
WO2010028275A1 (en) * 2008-09-05 2010-03-11 Xoma Technology Ltd. METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES

Similar Documents

Publication Publication Date Title
JP2013537539A5 (en)
AlGhamdi et al. Treatment of generalized vitiligo with anti-TNF-a agents
JP2014533279A5 (en)
BR112014022812A2 (en) human cd27 antibodies, methods and uses
HRP20250472T1 (en) ANTI-ALPHA4BETA7 ANTIBODIES DOSAGE REGIME
JP2013501814A5 (en)
RU2013110844A (en) ANTIBODIES AGAINST IL-1β AND IL-18 USED FOR TREATMENT OF DISEASES
JP2014513722A5 (en)
JP2009539841A5 (en)
JP2014530226A5 (en)
JP2016500251A5 (en)
NZ629178A (en) Antibodies to matrix metalloproteinase 9
WO2018223923A1 (en) Use of pd-1 antibody combined with vegf ligand or vegf receptor inhibitor in preparing drug for treating tumor
IL225310A (en) Use of an il-17 antibody for the manufacture of a medicament for treating psoriasis
JP2013538796A5 (en)
JP2020510039A5 (en)
RU2017120361A (en) ANTIBODIES TO PDGF-B AND WAYS OF THEIR APPLICATION
JP2016509585A5 (en)
FI3452513T3 (en) Humanized anti-il-1r3 antibodies
Zeng et al. Antibody therapies in autoimmune inflammatory myopathies: promising treatment options
FI3687567T3 (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
JP2017520562A5 (en)
MX345019B (en) Novel anti-human ctgf antibody.
HRP20161147T1 (en) PHARMACEUTICAL COMPOSITION AND PROCEDURE OF ITS MANUFACTURING
Lamot et al. The'head-to-head'comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis